Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 654 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/1/1995


1.		Phase II/III Randomized Study of CDDP/5-FU vs CDDP/5-FU/IFN-A for Metastatic Pancreatic Cancer (Summary Last Modified 02/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 75								EORTC-40924

Last Modified: 9/22/2005


2.		Phase II/III Randomized Study of Interleukin-2 and Interferon alfa With Versus Without Fluorouracil for Metastatic Renal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 79								FRE-FNCLCC-95009 EU-96026

Last Modified: 1/1/2000 First Published: 6/1/1999


3.		Phase II/III Randomized Study of SCH 54031 (Polyethylene Glycol Interferon alfa-2b) Versus Interferon alfa-2b in Patients With Newly Diagnosed Chronic Phase Myelogenous Leukemia (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70				Pharmaceutical / Industry				SPRI-C98-026 SPRI-C98-026-054, SPRI-I98-026

Last Modified: 12/29/2008 First Published: 1/1/1994


4.		NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Study of Melphalan/Total Body Irradiation with Peripheral Blood Stem Cell Rescue vs VBMCP (Vincristine/Carmustine/Melphalan/Cyclophosphamide/Prednisone) Following Standard Induction for Previously Untreated Symptomatic Multiple Myeloma, with Further Randomization for Major Responders to Interferon alfa vs Observation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				70 and under				NCI				SWOG-9321 CLB-9312, E-S9321, INT-0141, NCT00002548

Last Modified: 11/30/2007 First Published: 4/1/1994


5.		Phase III Randomized Study of Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone (VBMCP) Alone Versus VBMCP Alternating First With High-Dose Cyclophosphamide and Then With Interferon alfa in Patients With Previously Untreated Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-5A93 NCT00002556, E5A93

Last Modified: 2/1/1996


6.		Phase III Randomized Study of IFN-A with vs without 13-CRA in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 02/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				any age				NCI				MSKCC-94004 E-2894, NCI-T93-0198D, T93-0198

Last Modified: 5/8/2007 First Published: 11/1/1994


7.		Phase III Randomized Study of Standard Therapy with ABCM (DOX/BCNU/CTX/L-PAM) vs Intensive Therapy with C-VAMP (CTX/VCR/DOX/MePRDL) Followed by High-Dose L-PAM (with or without TBI) with Hematopoietic Rescue, Both with IFN-A Maintenance, for Previously Untreated Myeloma (Summary Last Modified 03/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 65								MRC-LEUK-MYEL-VII EU-94030, NCT00002599

Last Modified: 3/1/1999


8.		Phase III Randomized Study of Maintenance Therapy with IFN-A vs Placebo for Intermediate- and High-Grade non-Hodgkin's Lymphoma in Complete or Partial Remission Following Salvage Chemotherapy (Summary Last Modified 03/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				SPRI-C94-105/I94-105 SCH-C94-105, SCH-I94-105, NCI-V95-0665

Last Modified: 5/8/2007 First Published: 5/1/1996


9.		Phase III Randomized Study of Interferon alfa With Versus Without Isotretinoin in Patients With Metastatic Renal Cell Cancer (Summary Last Modified 04/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75								EORTC-30951 NCT00002737

Last Modified: 8/2/2007 First Published: 6/1/1996


10.		Phase III Randomized Study of Adjuvant Intermediate High-Dose IFN-A vs Intermediate Low-Dose IFN-A vs Observation Following Definitive Resection of Thick Primary and/or Regional Lymph Node Metastases in High-Risk Stage III Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 75								EORTC-18952 NCT00002763

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute